Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Schizophrenia (Sep 2020)

Posted by Matt Breese on Sep 18, 2020

Find me on:

According to our recent payer coverage analysis for schizophrenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for schizophrenia treatments shows that under the pharmacy benefit, about 26% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Schizophrenia-3Q2020Data snapshot as of Q3 2020

Trends: In December 2019, the FDA approved Intra-Cellular Therapies, Inc.’s Caplyta (lumateperone) for the treatment of schizophrenia in adults. The drug is an oral, once-daily medicine and is being developed for the treatment of bipolar depression; behavioral disturbances in patients with dementia, including Alzheimer’s disease; depression; and other neuropsychiatric and neurological disorders.  

To read the full Reality Check on Schizophrenia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing